Home > Riviste > Minerva Anestesiologica > Fascicoli precedenti > Minerva Anestesiologica 2016 March;82(3) > Minerva Anestesiologica 2016 March;82(3):343-58

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA ANESTESIOLOGICA

Rivista di Anestesia, Rianimazione, Terapia Antalgica e Terapia Intensiva


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

REVIEWS  


Minerva Anestesiologica 2016 March;82(3):343-58

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of genomics to identify biomarkers and signaling molecules during severe sepsis

James J. DOUGLAS , James A. RUSSELL

Centre for Heart Lung Innovation, St. Paul’s Hospital and University of British Columbia, Division of Critical Care Medicine, Vancouver, Canada


FULL TEXT  


Early strategies to diagnose, manage and predict outcome of sepsis are essential to further improve morbidity and mortality of sepsis. Whereas biomarkers have become mainstay in other fields of medicine, their clinical utility in sepsis remains generally much less proven and so biomarkers are much less used clinically. The Human Genome Project embellished genomics, transcriptomics, proteomics and metabolomics and continues to expand our knowledge of the genetic, gene expression, protein translational and metabolic discoveries that could lead to clinical biomarker tests related to sepsis thereby allowing insight into the disease as never seen before. We explore the genomic approach to biomarker identification and validation by reviewing pertinent studies related to the diagnosis (diagnostic biomarkers), prediction of response to therapies (predictive biomarkers) and (prognostic biomarkers) outcomes of sepsis.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

josh.douglas@hli.ubc.ca